Abstract: A combination of antitumor agents significantly shrinks tumors by synergistic antitumor action without increasing side effects to the extent possible. The antitumor composition contains compound (B) or a salt thereof for use in combination with antitumor agent (A), where (A) is at least one antitumor agent selected from alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors; and (B) is a compound or a salt thereof represented by formula (1): where R1 is halogen, aryl, aryloxy, or lower alkyl optionally substituted with one or more halogen atoms; R2 is hydrogen, halogen, lower alkyl, or lower alkoxy; and m=1 to 3, provided that when m is 2 or 3, each R1 is the same or different.

Abstract: A detection device for detecting a substance to be detected contained in a specimen has a pipette that has a detachable pipette tip and that suctions or discharges a specimen in a container, a pipette-moving unit for moving the pipette, and a control unit for controlling the pipette and pipette-moving unit. The control unit controls the pipette and the pipette-moving unit so that the pipette suctions a portion of specimen in the container with the pipette-moving unit having moved the distal end of the pipette tip to a position (a) in the lower side of the container, and thereafter discharges in the container the specimen suctioned by the pipette to stir the specimen with the pipette-moving unit having moved the distal end of the pipette tip to a position (b) above the position (a).

Abstract: The ingestible event marker data framework provides a uniform, comprehensive framework to enable various functions and utilities related to ingestible event marker data (IEM data). The functions and utilities include data and/or information having an aspect of data derived from, collected by, aggregated by, or otherwise associated with, an ingestion event.

Abstract: Apparatuses for use with a pharmaceutically acceptable carrier. The apparatus can include a partial power source, which in turn includes electrodes or materials that are configured to generate an electrical potential upon contacting or being exposed to an ionic solution. The apparatus can further include a circuit electrically or communicatively coupled to the partial power source. The circuit can generate various types of signals, such as RF signals, when powered by the partial power source. The circuit is stably fittable to the pharmaceutically acceptable carrier. The apparatus can further include a barrier, a protective layer, or a membrane that isolates the electrodes or materials from the ionic solution and is configured to be dissolved by the ionic solution.

Abstract: To provide a method for manufacturing an optical element, which improves the surface precision of the optical surface as well as reducing the birefringence at a low cost. A method for manufacturing an optical element 1090A having optical surfaces 1091 and 1092 and a non-optical surface 1093A that is adjacent to the optical surface 1092 via a ridge by injection molding includes forming the non-optical surface 1093A with a mold surface. The mold surface includes a sink forming area 1095 as a first area having a first surface roughness, and a high transfer area 1094 as a second area having a second surface roughness different from the first surface roughness. The second area is located outside the first area.

Abstract: By irradiating a sensor chip including an analyte labeled with a fluorescent substance with excitation light from an excitation light irradiation unit for emitting the excitation light using a specimen detector including the excitation light irradiation unit and a fluorescence detection unit for detecting fluorescence, fluorescence emitted from the fluorescent substance is detected by the fluorescence detection unit. When the analyte is detected on the basis of a detection value depending on the intensity of the detected fluorescence, a corrected detection value is calculated by correcting the detection value using individual difference information acquired in advance on the basis of an individual difference between the specimen detectors and a correction coefficient for each sensor chip.

Abstract: This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide, and in particular to novel physical forms of the compound, a process for preparing the compound and synthetic intermediates for use in the process, and novel formulations containing the compound, as well as therapeutic uses of the compound.

Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.

Abstract: A means for reducing side effects of tolvaptan is provided. Specifically, the means provides a pharmaceutical composition comprising a compound represented by Formula (1): or a metal salt thereof, wherein the pharmaceutical composition is used such that the compound represented by Formula (1) or a metal salt thereof is transvascularly administered in an amount of 4 to 20 mg over a period of 10 minutes or more.

Abstract: The present invention provides a composition for improvement in physical activity efficiency, a composition for reducing fatigue, and a composition for improving dynamic/kinetic visual acuity, comprising a plant-derived extract and/or a plant-derived processed product.

Abstract: The present invention provides a composition for suppressing muscular atrophy, comprising as an active ingredient(s) one or more peptides selected from the group consisting of tripeptides DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP, and NPK; the group consisting of dipeptides comprising F; and the group consisting of dipeptides DI, IY, YN, and NP.

Abstract: A test kit of the present invention includes an analysis chip and a pipette tip. The pipette tip includes: a first portion coming in contact with an insertion hole hermetic seal when the pipette tip is inserted into a pipette tip insertion portion so as to allow a liquid dispensation port to be positioned at or in the vicinity of a bottom surface of the pipette tip insertion portion; and a second portion positioned closer to the liquid dispensation port side than the first portion. The outer diameter of the second portion is formed to be equal to or greater than the outer diameter of the first portion and any portion between the first portion and the second portion.

Abstract: In some embodiments, a system includes a first assembly, a second assembly, and a connecting member. The first assembly includes a first electrode and a first adhesive portion. The first assembly is configured to be coupled to a surface of a patient via the first adhesive portion. The second assembly includes a second electrode and a second adhesive portion. The second assembly is configured to be coupled to the surface of the patient via the second adhesive portion. The connecting member has a first end coupled to the first assembly and a second end coupled to the second assembly. The connecting member is configured to transition between a first configuration and a second configuration and may be configured to be coupled to the surface of the patient via a third adhesive portion in both the first configuration and the second configuration.

Abstract: The present invention relates to a method of mono-deuterated-lower-alkylating the amine part in a compound having an amine protected with an aralkyl, which comprises introducing mono-deuterated lower-alkyl into the amine with a deuterated-lower-alkylating agent under neutral or basic condition, and then deprotecting the aralkyl group.

Abstract: An object of the disclosure is to provide a composition for evaluating the hepatic glucose uptake capacity of a subject and a method for evaluating the hepatic glucose uptake capacity of a subject with the composition. An object of the disclosure is to provide a method for determining the stage of pre-onset diabetes in a subject with pre-onset diabetes using the method for evaluating the hepatic glucose uptake capacity. An aspect of the disclosure accordingly provides a composition comprising 13C-labeled glucose for evaluating the hepatic glucose uptake capacity of a subject. Another aspect of the disclosure provides a method comprising measuring 13C-labeled glucose in a blood sample or an expired air sample obtained from the subject to which the composition was administered. The desired evaluation or determination can be achieved by comparing the measured value with a reference value.

Abstract: An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin.

Abstract: In some embodiments, a system includes a patch assembly, a frame, and a conductive component. The patch assembly is configured to be coupled to a patient via an adhesive portion. The patch assembly includes an electronics subassembly. The frame has a first frame configuration in which the frame is coupled to the patch assembly via a plurality of connectors and a second frame configuration in which the plurality of connectors are broken and the frame is separated from the patch assembly. The conductive component forms a continuous loop when the frame is in the first frame configuration. A portion of the conductive component is broken when the frame is in the second frame configuration such that the conductive component is discontinuous between the first end and the second end. The portion of the conductive component is at least partially disposed on a connector from the plurality of connectors when the frame is in the first frame configuration.

Abstract: In some embodiments, a system includes a patch assembly and a frame. The patch assembly includes an adhesive portion. The patch assembly is configured to be coupled to a surface of a user via the adhesive portion. The patch assembly has a first patch configuration and a second patch configuration. The frame defines an opening. The patch assembly is configured to be disposed within the opening. The frame has a first frame configuration in which the frame is coupled to the patch assembly via a group of connectors such that the frame prevents the patch assembly from transitioning between the first patch configuration and the second patch configuration. The frame has a second frame configuration in which the group of connectors are broken and the frame is separated from the patch assembly.

Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.

Abstract: Provided herein are compositions for the ingestible administration of lisinopril. In some embodiments the compositions comprise lisinopril and silicon. In some embodiments, the compositions comprise lisinopril, silicon, magnesium metal, and copper (I) chloride. Also provided herein are apparatuses comprising the compositions provided herein. Also provided herein are methods for using the compositions and apparatuses provided herein.